Autolus Therapeutics (AUTL) Misses Q1 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wells Fargo Reiterates Overweight Rating on Autolus Therapeutics plc (AUTL)
May 20, 2024 6:43 AM EDTWells Fargo analyst Yanan Zhu reiterated an Overweight rating and $8.00 price target on Autolus Therapeutics plc (NASDAQ: AUTL).
The analyst comments "We continue to see AUTL as well positioned for upside on 2H24 catalysts incl. B-ALL PDUFA (11/16) and first SLE data (late... More
